About: Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 10 February 2012

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 2012 (uk) scientific article published on 10 February 2012 (en) 2012 թվականի փետրվարի 10-ին հրատարակված գիտական հոդված (hy) artículu científicu espublizáu en febreru de 2012 (ast) im Februar 2012 veröffentlicher wissenschaftlicher Artikel (de)
publication date	wds:Q83427167-B42C491B-8F5B-4712-88A7-711428180224
publication date	2012-02-10 00:00:00Z (xsd:dateTime)
cites work	wds:Q83427167-08830B67-30F8-424F-A74D-DDF787E36994 wds:Q83427167-0AFD1244-6093-4CD8-B0DD-73C7E0DBFA3F wds:Q83427167-0B6A583B-C723-4917-B4E1-7A1FA22FCA6D wds:Q83427167-10C87470-8F74-4B77-BE3D-A30B0711DFBE wds:Q83427167-13987FC9-6876-4AB5-A3AD-A54A39F258E9 wds:Q83427167-18148A8D-3421-482C-86C7-418A19F009C1 wds:Q83427167-3CCE99BC-2274-4401-8F20-68EB31F20F77 wds:Q83427167-4AA6A17E-25B9-40DF-B5CD-4CBC25CE0523 wds:Q83427167-52B9798A-C54C-4B3B-B45F-DDC490CFDDE9 wds:Q83427167-55E677FC-6E9D-4E9A-A58B-75EB6D45EA2D wds:Q83427167-6390F838-6753-4FBD-B193-B83A84B6ACA1 wds:Q83427167-687C3EE5-99B7-400B-B5B4-B75A5EF0A79C wds:Q83427167-7D1E78FC-DDCB-4798-824F-CE98B39D65B3 wds:Q83427167-8413D389-1C2A-4E1B-AAAC-559CF4D89D15 wds:Q83427167-8A98CBAF-B3F8-4EF5-92BD-C1C986E3AF74 wds:Q83427167-8FE0ECFC-71A6-44A7-B00B-E8205F045015 wds:Q83427167-9BA5231B-E20C-47FF-8E72-EC1F8B8B94C6 wds:Q83427167-A6370C1E-BD20-4BFE-BAEB-4BA3FE822B64 wds:Q83427167-B6FE9A7B-25B0-43D6-96A1-70D33C1A9D63 wds:Q83427167-BCDC1AD6-1050-4394-BBBB-3B564C0BF477 wds:Q83427167-C30A1C62-CC11-4728-8021-C18982B45BA5 wds:Q83427167-D1EBCF7B-EA6F-448E-B9C5-C0A122A1A9D8 wds:Q83427167-D2CB2E5E-0BFA-4838-BD28-FA43DDD493CE wds:Q83427167-DED9BBAC-4E35-4676-A1D3-18D9942256AE wds:Q83427167-EE0A84F4-393F-448E-95DE-A7979A43E5B5 wds:Q83427167-FB16BB05-1298-4933-8CD6-9ADE097B335E wds:Q83427167-FEBA0FF6-ED32-407F-B00A-B4BDAFD2DA9B
cites work	Multiple costimulatory modalities enhance CTL avidity Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer Sipuleucel-T immunotherapy for castration-resistant prostate cancer Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma Global cancer statistics Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma CTLA-4: new insights into its biological function and use in tumor immunotherapy A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer Clinical safety of a viral vector based prostate cancer vaccine strategy Phase I/II study of ipilimumab for patients with metastatic melanoma MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor
author name string	wds:Q83427167-02B5393C-5A6D-4D8C-B58D-09220790DB4D wds:Q83427167-2A8DADEA-979B-417A-8258-A111A2F70AA6 wds:Q83427167-5AC40F0F-4B15-4968-B6D8-FAEFFC2CF055 wds:Q83427167-8460EDA1-7881-433C-8198-3E439B009510 wds:Q83427167-9372109B-BD63-4940-96DA-14EEAE9BF20C wds:Q83427167-9F723A0E-0CB8-48AE-8307-EFB2D59D681F wds:Q83427167-C10EC3FC-C253-431D-8D84-32B498478BCA wds:Q83427167-CEA0D4B1-09B7-4306-936E-273FD067105E wds:Q83427167-DA9B4D61-AAB5-4485-9DD9-73DBBB7CE2D4 wds:Q83427167-EBBA00D6-68E8-4A2E-9F03-653F2C88B5E9 wds:Q83427167-FF581D42-BD97-426C-91C3-6FDC11ECAF18
author name string	John J Wright Seth M Steinberg Howard L Parnes Kwong Y Tsang Ravi A Madan Philip M Arlen William L Dahut Diane J Poole Matteo Vergati Mahsa Mohebtash Myrna Rauckhorst
rdfs:label	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial (en) Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial (nl)
skos:prefLabel	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial (en) Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial (nl)
name	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial (en) Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial (nl)
author	wds:Q83427167-569B82AD-1CBD-4469-8354-D0501B20232D wds:Q83427167-A976B59A-8058-4644-8C0E-2AF2100878EB
author	James L. Gulley Jeffrey Schlom
title	wds:Q83427167-47DAB283-F907-48D2-B212-61AD6FADF4CE
title	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial (en)
page(s)	wds:Q83427167-E345281D-C4FA-416C-86FC-C40037650C15
page(s)	501-508
instance of	wds:Q83427167-F9E12593-3935-43E4-88AB-762C94610B69

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 150 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software